Services
$200 Consulting fee – to see if it is right for you (excludes prescription cost)*
Impact of Physical Arousal (Bremelanotide)
Many of us are unfortunately familiar with the fact that sex drive tends to decline with age. But this doesn’t have to be the case! Bremelanotide PT-141 is a peptide that can reinvigorate your sex drive and help you reclaim the passion you felt in your younger years. This natural peptide can treat sexual health dysfunction and a variety of other health concerns.
What is Bremelanotide PT-141?
Bremelanotide PT-141 is a synthetic peptide that is mainly used to treat sexual dysfunction in both men and women. When injected, PT-141 activates melanocortin receptors in the brain, and these receptors increase sexual desire and arousal.
Originally developed from a hormone that triggers skin tanning, this peptide was shown to have the pleasant side effects of improved sexual arousal and erections. Since then, further study has shown that PT-141 is an incredible treatment for sexual dysfunction and has the potential to help men and women revitalize their sex lives.
Bremelanotide PT-141 can help to treat a variety of sexual dysfunction issues, including: Low sexual arousal, Poor sensation during intercourse, Inability to orgasm, Pain during sex, Emotional issues related to sex (Source)
How Does Bremelanotide PT-141 Treat Sexual Dysfunction?
While many sexual dysfunction treatments target the vascular system, Bremelanotide PT-141 takes a different approach. This peptide directly stimulates the nervous system to increase dopamine and other chemicals that enhance sexual appetite and pleasure.
Bremelanotide PT-141 is effective against the negative impacts of sexual dysfunction for both men and women. As a bonus, this peptide has also shown potential in reducing stress, regulating appetite and mood, and boosting the immune system. (Source)
Food and Drug Administration (FDA)
The U.S. Food and Drug Administration today [June 21, 2019] approved Vyleesi (bremelanotide) to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.
“There are women who, for no known reason, have reduced sexual desire that causes marked distress, and who can benefit from safe and effective pharmacologic treatment. Today’s approval provides women with another treatment option for this condition,” said Hylton V. Joffe, M.D., M.M.Sc., director of the Center for Drug Evaluation and Research’s Division of Bone, Reproductive and Urologic Products. “As part of the FDA’s commitment to protect and advance the health of women, we’ll continue to support the development of safe and effective treatments for female sexual dysfunction.”
HSDD is characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, problems within the relationship or the effects of a medication or other drug substance. Acquired HSDD develops in a patient who previously experienced no problems with sexual desire. Generalized HSDD refers to HSDD that occurs regardless of the type of sexual activity, situation or partner.
Vyleesi activates melanocortin receptors, but the mechanism by which it improves sexual desire and related distress is unknown. Patients inject Vyleesi under the skin of the abdomen or thigh at least 45 minutes before anticipated sexual activity and may decide the optimal time to use Vyleesi based on how they experience the duration of benefit and any side effects, such as nausea. Patients should not use more than one dose within 24 hours or more than eight doses per month. Patients should discontinue treatment after eight weeks if they do not report an improvement in sexual desire and associated distress.
The effectiveness and safety of Vyleesi were studied in two 24-week, randomized, double-blind, placebo-controlled trials in 1,247 premenopausal women with acquired, generalized HSDD. Most patients used Vyleesi two or three times per month and no more than once a week. In these trials, about 25% of patients treated with Vyleesi had an increase of 1.2 or more in their sexual desire score (scored on a range of 1.2 to 6.0, with higher scores indicating greater sexual desire) compared to about 17% of those who took placebo. Additionally, about 35% of the patients treated with Vyleesi had a decrease of one or more in their distress score (scored on a range of zero to four, with higher scores indicating greater distress from low sexual desire) compared to about 31% of those who took placebo. There was no difference between treatment groups in the change from the start of the study to end of the study in the number of satisfying sexual events. Vyleesi does not enhance sexual performance.
The most common side effects of Vyleesi are nausea and vomiting, flushing, injection site reactions and headache. About 40% of patients in the clinical trials experienced nausea, most commonly with the first Vyleesi injection, and 13% needed medications for the treatment of nausea. About 1% of patients treated with Vyleesi in the clinical trials reported darkening of the gums and parts of the skin, including the face and breasts, which did not go away in about half the patients after stopping treatment. Patients with dark skin were more likely to develop this side effect. (Source)